Sensory neuronopathy associated with tumor necrosis factor inhibitor therapy
نویسندگان
چکیده
منابع مشابه
Tumor necrosis factor inhibitor-associated dermatomyositis.
BACKGROUND Dermatomyositis is an autoimmune disease of unknown etiology characterized by inflammation of the skin and muscles. Several medications have been implicated in the development of dermatomyositis; however, the disease has rarely been linked to the use of tumor necrosis factor (TNF) inhibitors. We report 4 cases of dermatomyositis that developed or were exacerbated by exposure to the T...
متن کاملNeuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
Biologic tumor necrosis factor (TNF)-α inhibitors do not cross the blood-brain barrier (BBB). A BBB-penetrating TNF-α inhibitor was engineered by fusion of the extracellular domain of the type II human TNF receptor (TNFR) to the carboxyl terminus of the heavy chain of a mouse/rat chimeric monoclonal antibody (MAb) against the mouse transferrin receptor (TfR), and this fusion protein is designat...
متن کاملCerebellar atrophy is frequently associated with non-paraneoplastic sensory neuronopathy
Sensory neuronopathies (SN) are peripheral nervous system disorders associated with degeneration of dorsal root ganglion neurons. Despite the evidence of a defective proprioceptive sensory input in SN, the prominent gait and truncal ataxia raises the question of a concomitant involvement of the cerebellum. Objective: To evaluate cerebellar atrophy in SN. Method: We analyzed MRI-based volumetry ...
متن کاملAssociation Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
OBJECTIVE Patients with rheumatoid arthritis (RA) are at an increased risk of ischemic stroke. Tumor necrosis factor inhibitors (TNFi) may influence risk and mortality after ischemic stroke by reducing inflammation. This study was undertaken to examine the association of TNFi with the risk of incident ischemic stroke and with 30-day and 1-year mortality after ischemic stroke. METHODS Patients...
متن کاملLong-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy
There are no treatment modalities, which were proven to prevent the deposition of amyloid, proteinuria, and loss of renal function due to amyloidosis. Anti-tumor necrosis factor agents (anti-TNFs) were shown to decrease the production of serum amyloid A protein.We aimed to evaluate the long-term efficacy and safety of anti-TNFs in secondary (AA) amyloidosis patients treated in a single center.T...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology: Clinical Practice
سال: 2014
ISSN: 2163-0402,2163-0933
DOI: 10.1212/cpj.0000000000000010